BLTE logo

BLTE
Belite Bio Inc

266
Mkt Cap
$6.68B
Volume
208,138.00
52W High
$200.00
52W Low
$49.00
PE Ratio
-73.92
BLTE Fundamentals
Price
$171.17
Prev Close
$169.85
Open
$170.28
50D MA
$170.81
Beta
0.66
Avg. Volume
181,870.24
EPS (Annual)
-$2.31
P/B
8.67
Rev/Employee
$0.00
$4,872.77
Loading...
Loading...
News
all
press releases
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold ratin...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Belite Bio from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·3d ago
News Placeholder
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Grows By 25.1%
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) saw a large growth in short interest in March. As of March 13th, there was short interest totaling 990,833 shares, a growth of 25.1% from the February 26th total of 792,323 shares. Approximately 2.9% of the company's shares are short...
MarketBeat·7d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Belite Bio from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·17d ago
News Placeholder
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) has been given an average rating of "Moderate Buy" by the eight ratings firms that are currently covering the stock, MarketBeat Ratings...
MarketBeat·26d ago
News Placeholder
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference
Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl outlined the company's approach to treating Stargardt disease and reviewed top-line results from its Phase 3 DRAGON trial during a...
MarketBeat·27d ago
News Placeholder
Belite Bio (BLTE) to Release Earnings on Monday
Belite Bio (NASDAQ:BLTE) will be releasing its Q4 2025 earnings before the market opens on Monday, March 16. (View Earnings Report at...
MarketBeat·29d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Belite Bio from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2026 EPS estimates for Belite Bio in a research note issued on Tuesday, March 3rd. HC...
MarketBeat·1mo ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright
HC Wainwright upped their price objective on shares of Belite Bio from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Tuesday...
MarketBeat·1mo ago
<
1
2
...
>

Latest BLTE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.